DEFA14A - NanoVibronix, Inc. (0001326706) (Filer)

DEF 14A - NanoVibronix, Inc. (0001326706) (Filer)

PRE 14A - NanoVibronix, Inc. (0001326706) (Filer)

8-K - NanoVibronix, Inc. (0001326706) (Filer)

10-Q - NanoVibronix, Inc. (0001326706) (Filer)

SCHEDULE 13G - NanoVibronix, Inc. (0001326706) (Subject)

8-K - NanoVibronix, Inc. (0001326706) (Filer)

424B4 - NanoVibronix, Inc. (0001326706) (Filer)

NT 10-Q - NanoVibronix, Inc. (0001326706) (Filer)

EFFECT - NanoVibronix, Inc. (0001326706) (Filer)

Dual-System Agreement Highlights Transition Towards Advanced Bedside Navigation NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic devices, announced today that a regional acute care hospital in upstate New York has signed an agreement to acquire two ENvue™ Navigation Systems through its ENvue Medical division ("ENvue" or "ENvue Medical"). The systems, which are currently expected to be delivered in the third quarter of 2025, will support bedside placement of nasoenteric feeding tubes in adult patients. ENvue's electromagnetic technology provides clinicians with real-time visualization of tube directi

Patent strengthens ENvue's IP position as it advances toward pediatric regulatory clearance and expanded clinical use NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division ("ENvue Medical" or "ENvue"), a new U.S. patent for its pediatric feeding tube guidance system. U.S. Patent No. 12,324,632, titled "Insertion Device Positioning Guidance System," further strengthens ENvue Medical's intellectual property portfolio and reflects the Company's ongoing commitment to innovation in feeding tube placement technologies. This newly granted patent cover

NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the retirement of Brian Murphy as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Doron Besser, CEO of ENvue Medical Holdings, LLC ("ENvue"), a wholly-owned subsidiary of the Company, as NanoVibronix's new CEO, also effective immediately. Mr. Murphy will remain on the Company's Board of Directors as a director. His continued service will support governance continuity at the Board level. As previously announced, on February 14, 2025, the Company consummated and completed its acquisition of ENvue,

NanoVibronix, Inc. (the "Company") (NASDAQ:NAOV) confirmed that a series of posts made earlier today with respect to a $26 million registered direct offering of common stock of the Company priced at $0.45 under Nasdaq rules was falsely issued by Flash Alert and FintelAlerts. The Company has not priced and is not consummating any registered direct offering. The Company is actively investigating this misinformation and will take necessary actions to protect its stockholders and its reputation. View source version on businesswire.com: https://www.businesswire.com/news/home/20250528125762/en/ Brett Maas, Managing Principal Hayden IR, LLC [email protected] (646) 536-7331

Greater New Orleans Area Facility to Transition from Blind Insertions to FDA-Cleared Electromagnetic Guidance NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division ("ENvue Medical"), that a major 420-bed acute care hospital located in the greater New Orleans area has selected the ENvue™ Navigation Platform (the "ENvue System") to support adult feeding tube procedures. The hospital will transition from traditional blind insertions to real-time, electromagnetic-guided placement using the ENvue System. The ENvue System is FDA-cleared for nasoenter

NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the closing of its previously announced underwritten public offering of 400,000 shares of the Company's Series G Convertible Preferred Stock ("Preferred Stock"), with a par value $0.001 per share and a stated value equal to $25, and Warrants to purchase up to 4,901,982 shares of common stock, par value $0.001 per share (the "Common Stock") of the Company at an exercise price of $2.04 per share (the "Warrants"). The combined public offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00. The Warrants have

NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the pricing of an underwritten public offering of approximately 400,000 shares of the Company's Series G Convertible Preferred Stock ("Preferred Stock"), par value $0.001 per share and Warrants to purchase up to 4,901,961 shares of common stock, par value $0.001 per share (the "Common Stock") of the Company at an exercise price of $2.04 per share (the "Warrants"). The combined public offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00. The closing of the public offering is expected to occur on or abo

UroShield Demonstrates Significant Reductions in CAUTIs, Catheter Blockages and Hospital Visits NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical technology company specializing in therapeutic devices, today announced findings from a recent retrospective case series evaluating the clinical impact and patient experience of the UroShield™ system. The case series, conducted between September 2023 and January 2025 by researchers at University Hospitals Coventry and Warwickshire Partnership NHS, assessed a small group of patients who used the UroShield device for durations ranging from 12 weeks to 17 months. The series reviewed pre- and post-treatment data on catheter-associated urin

NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company" or "NanoVibronix"), a medical technology company specializing in non-invasive therapeutic devices, today announced that on April 9, 2025, Nasdaq formally notified the Company that it has evidenced full compliance with all criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price and $2.5 million stockholders' equity requirements. Accordingly, the previously disclosed Nasdaq listing matter has been closed. Pursuant to Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor until April 9, 2026. About NanoVibronix, Inc. NanoVibronix, Inc. (NASDAQ:NAOV) is a medical device company hea

Publication of Independent Study Heightens Demand for UroShield NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company" or "NanoVibronix"), a medical technology company specializing in non-invasive therapeutic devices, today announced the renewal and expansion of its exclusive three-year distribution agreement with Dukehill Healthcare Pty Ltd. ("Dukehill"). Dukehill, with its Head Office in Queensland, has primarily focused its clinical projects and sales efforts within the state and in New South Wales. However, the recent expansion of the agreement with the Company now extends across all Australian States, with notable growth in South Australia and Victoria. This surge follows an increasing numb